{
  "pmcid": "11645970",
  "sha256": "405dfbf91dba6a8a25034bd144b8e7f437c8b830c03525c3d309361236e478d5",
  "timestamp_utc": "2025-11-09T23:18:33.039540+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.615361570247938,
    "reading_ease": 10.04758780991736,
    "word_count": 242
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of High-Dose Magnesium Sulfate Infusion for Opioid-Sparing Analgesia in Pediatric Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "prospective trial with a retrospective control group"
      },
      "Participants": {
        "score": 2,
        "evidence": "participants aged 3â€“18 years undergoing total pancreatectomy with islet cell autotransplantation or liver transplantation"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention involved a MgSO4 bolus (50 mg/kg) followed by an infusion (15 mg/kg/h) for up to 48 hours."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial evaluated the feasibility of high-dose magnesium sulfate (MgSO4) infusion for analgesia in pediatric transplant recipients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was oral morphine equivalent (OME) per kg per day during the PICU stay."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and blinding details were not applicable."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Randomisation and blinding details were not applicable."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Eleven patients were enrolled from July 2020 to December 2022."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "The treatment group showed a trend towards higher intravenous fluid requirement (~1 bolus) but no increase in blood product use."
      },
      "Harms": {
        "score": 1,
        "evidence": "No serious adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "NCT04812028"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: University of Minnesota Department of Pediatrics."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}